EXPLORE!

US FDA Approved Alectinib as Adjuvant Treatment for ALK-positive NSCLC

  65 Views

Emedinexus    20 November 2024

Alectinib has indeed been approved by the US FDA for use as adjuvant treatment in patients with ALK-positive non-small cell lung cancer (NSCLC) following tumor resection.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.